Aquí los links a los artículos: Herold KC, Bundy BN, Long SA, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019;381(7):603-613. doi:10.1056/NEJMoa1902226. https://t.co/b6SurEN1Ha Insel RA, Dunne JL, Atk…
Sources and notes. 1. Casgevy (exa-cel, Vertex + CRISPR Therapeutics), FDA approved Dec 2023 for sickle cell disease. CRISPR editing of the patient's own stem cells; pivotal CLIMB trial (NCT03745287): https://t.co/pngEdzBxt0 Results (ASH 2023): https:/…
Efectos sobre función β: otros estudios (incluyendo NEJM y datos fase 3) mostraron preservación de C-péptido y mejor conservación de la función secretora frente a placebo, lo que apoya el efecto biológico sobre las células β https://t.co/bKDEeWGdpU
@Tholhaths Median time to the diagnosis of type 1 diabetes was 48.4 months in the teplizumab group and 24.4 months in the placebo group; the disease was diagnosed in 19 (43%) of the participants who received teplizumab and in 23 (72%) of those who recei…